{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:12:41Z","timestamp":1793157161365,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This is, to our knowledge, the first network meta-analysis aiming to compare all treatment modalities for myopic choroidal neovascularization (CNV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After the electronic databases were searched, two independent reviewers screened titles, abstracts, full-texts, and extracted information. Primary endpoints were change in visual outcome and central retinal thickness. We used a network meta-analysis to compare treatment outcomes in the early (\u2264\u20096\u00a0months) and late (&gt;\u20096\u00a0months) phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 34 studies (2,098 eyes) in our network meta-analysis. In the early phase, the use of anti-VEGF led to a gain of 14.1 letters (95% CI, 10.8\u201317.4) compared to untreated patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), 12.1 letters (95% CI, 8.3\u201315.8) to photodynamic therapy (PDT) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), 7.5 (95% CI, 1.2\u201313.8) letters to intravitreal triamcinolone acetonide (TCA) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019), and\u2009\u2212\u20092.9 letters (95% CI,\u2009\u2212\u20096.0\u20130.2) to the combination of anti-VEGF and PDT (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.065). In the later phase, these results were largely maintained. There were no significant differences in visual outcomes between patients treated with 1\u2009+\u2009PRN and 3\u2009+\u2009PRN. However, the 1\u2009+\u2009PRN group received 1.8 (SD 1.3), while the 3\u2009+\u2009PRN group received 3.2 (SD 0.9) injections within 12\u00a0months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This network meta-analysis confirms that anti-VEGF is the most effective treatment for myopic CNV using the 1\u2009+\u2009PRN treatment strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-023-06271-2","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T02:02:03Z","timestamp":1699668123000},"page":"1693-1722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of myopic choroidal neovascularization: a network meta-analysis and review"],"prefix":"10.1007","volume":"262","author":[{"given":"Laura","family":"Glachs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Embacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Berghold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Wildner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monja","family":"Michelitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tscherne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6394-6459","authenticated-orcid":false,"given":"Laura","family":"Posch-Pertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"key":"6271_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1136\/bmj.324.7347.1195","volume":"324","author":"DR Fredrick","year":"2002","unstructured":"Fredrick DR (2002) Myopia. BMJ (Clinical research ed) 324:1195\u20131199. https:\/\/doi.org\/10.1136\/bmj.324.7347.1195","journal-title":"BMJ (Clinical research ed)"},{"key":"6271_CR2","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","volume":"124","author":"C Cheung","year":"2017","unstructured":"Cheung C, Arnold JJ, Holz FG, Park KH, Lai TYY, Larsen M, Mitchell P, Ohno-Matsui K, Chen SJ, Wolf S, Wong TY (2017) Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology 124:1690\u20131711. https:\/\/doi.org\/10.1016\/j.ophtha.2017.04.028","journal-title":"Ophthalmology"},{"key":"6271_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","volume":"110","author":"KJ Blinder","year":"2003","unstructured":"Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology 110:667\u2013673. https:\/\/doi.org\/10.1016\/S0161-6420(02)01998-X","journal-title":"Ophthalmology"},{"key":"6271_CR4","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1097\/IAE.0b013e3181e22659","volume":"30","author":"JM Ruiz-Moreno","year":"2010","unstructured":"Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, Pi\u00f1ero DP (2010) Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina (Philadelphia, Pa) 30:1609\u20131615. https:\/\/doi.org\/10.1097\/IAE.0b013e3181e22659","journal-title":"Retina (Philadelphia, Pa)"},{"key":"6271_CR5","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1097\/IAE.0b013e3182109074","volume":"31","author":"L Chen","year":"2011","unstructured":"Chen L, Miller JW, Vavvas D, Kim IK (2011) Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration. Retin-J Retin Vitr Dis 31:2078\u20132083. https:\/\/doi.org\/10.1097\/IAE.0b013e3182109074","journal-title":"Retin-J Retin Vitr Dis"},{"issue":"1","key":"6271_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/1120672119883590","volume":"31","author":"A Howaidy","year":"2021","unstructured":"Howaidy A, Eldaly ZH (2021) Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization. Eur J Ophthalmol 31(1):211\u2013217. https:\/\/doi.org\/10.1177\/1120672119883590","journal-title":"Eur J Ophthalmol."},{"key":"6271_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/bjo.84.7.761","volume":"84","author":"H Kobayashi","year":"2000","unstructured":"Kobayashi H, Kobayashi K (2000) Radiotherapy for subfoveal neovascularisation associated with pathological myopia: a pilot study. Br J Ophthalmol 84:761\u2013766. https:\/\/doi.org\/10.1136\/bjo.84.7.761","journal-title":"Br J Ophthalmol"},{"key":"6271_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\u00e1-L\u00f3pez F, G\u00f8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777\u2013784. https:\/\/doi.org\/10.7326\/m14-2385","journal-title":"Ann Intern Med"},{"key":"6271_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed) 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ (Clinical research ed)"},{"key":"6271_CR10","doi-asserted-by":"publisher","first-page":"508","DOI":"10.14573\/altex.1902131","volume":"36","author":"S Van der Mierden","year":"2019","unstructured":"Van der Mierden S, Tsaioun K, Bleich A, Leenaars CHC (2019) Software tools for literature screening in systematic reviews in biomedical research. ALTEX 36:508\u2013517. https:\/\/doi.org\/10.14573\/altex.1902131","journal-title":"ALTEX"},{"key":"6271_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"6271_CR12","unstructured":"Higgins JPT, Li T, Deeks JJ (eds) (2022). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane. Available from www.training.cochrane.org\/handbook"},{"key":"6271_CR13","unstructured":"Balk EM, Earley A, Patel K, Trikalinos TA, Dahabreh IJ (2012) Empirical assessment of within-arm correlation imputation in trials of continuous outcomes [Internet]. Report No.: 12(13)-EHC141-EF. Agency for Healthcare Research and Quality (US), Rockville (MD)"},{"key":"6271_CR14","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1097\/IAE.0000000000000610","volume":"35","author":"DS Ng","year":"2015","unstructured":"Ng DS, Kwok AK, Tong JM, Chan CW, Li WW (2015) Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization. Retina 35:2457\u20132468. https:\/\/doi.org\/10.1097\/IAE.0000000000000610","journal-title":"Retina"},{"key":"6271_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Meta-analysis with R","author":"G Schwarzer","year":"2015","unstructured":"Schwarzer G, Carpenter JR, R\u00fccker G (2015) Meta-analysis with R. Springer International Publishing, Switzerland"},{"key":"6271_CR16","doi-asserted-by":"publisher","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O, Schwarzer G (2023) netmeta: an R Package for network meta-analysis using frequentist methods. J Stat Softw 106(2):1\u201340. https:\/\/doi.org\/10.18637\/jss.v106.i02","DOI":"10.18637\/jss.v106.i02"},{"key":"6271_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JP Higgins","year":"2012","unstructured":"Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3:98\u2013110. https:\/\/doi.org\/10.1002\/jrsm.1044","journal-title":"Res Synth Methods"},{"key":"6271_CR18","volume-title":"R foundation for statistical computing","author":"R Core Team","year":"2022","unstructured":"R Core Team (2022) R foundation for statistical computing. Austria, Vienna"},{"key":"6271_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ajo.2006.09.041","volume":"143","author":"A Glacet-Bernard","year":"2007","unstructured":"Glacet-Bernard A, Benyelles N, Dumas S, Haddad WM, Voigt M, Razavi S, Roquet W, Coscas G, Soubrane G (2007) Photodynamic therapy vs limited macular translocation in the management of subfoveal choroidal neovascularization in pathologic myopia: a two-year study. Am J Ophthalmol 143:68\u201376. https:\/\/doi.org\/10.1016\/j.ajo.2006.09.041","journal-title":"Am J Ophthalmol"},{"key":"6271_CR20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/s0002-9394(02)01335-1","volume":"133","author":"N Hamelin","year":"2002","unstructured":"Hamelin N, Glacet-Bernard A, Brindeau C, Mimoun G, Coscas G, Soubrane G (2002) Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am J Ophthalmol 133:530\u2013536. https:\/\/doi.org\/10.1016\/s0002-9394(02)01335-1","journal-title":"Am J Ophthalmol"},{"key":"6271_CR21","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/bjophthalmol-2012-303007","volume":"97","author":"A Miki","year":"2013","unstructured":"Miki A, Honda S, Nagai T, Tsukahara Y, Negi A (2013) Effects of oral bisphosphonates on myopic choroidal neovascularisation over 2 years of follow-up: comparison with anti-VEGF therapy and photodynamic therapy. A pilot study. Br J Ophthalmol 97:770\u2013774. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-303007","journal-title":"Br J Ophthalmol"},{"key":"6271_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/archophthalmol.2009.408","volume":"128","author":"MB Parodi","year":"2010","unstructured":"Parodi MB, Iacono P, Papayannis A, Sheth S, Bandello F (2010) Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 128:437\u2013442. https:\/\/doi.org\/10.1001\/archophthalmol.2009.408","journal-title":"Arch Ophthalmol"},{"key":"6271_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ajo.2009.05.026","volume":"148","author":"T Wakabayashi","year":"2009","unstructured":"Wakabayashi T, Ikeda Y, Gomi F, Tano Y, Hamasaki T (2009) Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia. Am J Ophthalmol 148:591\u2013596","journal-title":"Am J Ophthalmol"},{"key":"6271_CR24","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW (2016) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123:1351\u20131359. https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.022","journal-title":"Ophthalmology"},{"key":"6271_CR25","doi-asserted-by":"publisher","first-page":"CD004765","DOI":"10.1002\/14651858.CD004765.pub2","volume":"19","author":"G Virgili","year":"2005","unstructured":"Virgili G, Menchini F (2005) Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev 19:CD004765. https:\/\/doi.org\/10.1002\/14651858.CD004765.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"6271_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2174\/157489206778776989","volume":"1","author":"D Santini","year":"2006","unstructured":"Santini D, Schiavon G, Angeletti S, Vincenzi B, Gasparro S, Grilli C, La Cesa A, Virz\u00ed V, Leoni V, Budillon A, Addeo SR, Caraglia M, Dicuonzo G, Tonini G (2006) Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs? Recent Pat Anticancer Drug Discov 1:383\u2013396. https:\/\/doi.org\/10.2174\/157489206778776989","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"6271_CR27","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1136\/bjo.2009.166025","volume":"94","author":"T Baba","year":"2010","unstructured":"Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S (2010) Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 94:864\u2013870","journal-title":"Br J Ophthalmol"},{"key":"6271_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00417-003-0686-9","volume":"241","author":"F Bandello","year":"2003","unstructured":"Bandello F, Lanzatta P, Parodi MB, Roman-Pognuz D, Saviano S, Ravalico G (2003) Photodynamic therapy of subfoveal recurrences after laser photocoagulation of extrafoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 241:567\u2013570. https:\/\/doi.org\/10.1007\/s00417-003-0686-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6271_CR29","first-page":"1247","volume":"54","author":"F Bandello","year":"2013","unstructured":"Bandello F (2013) Twelve-month efficacy and safety of ranibizumab 0.5 mg (RBZ) versus verteporfin photodynamic therapy (vPDT) in the treatment of visual impairment (VI) due to choroidal neovascularization (CNV) secondary to pathologic myopia (PM). Invest Ophthalmol Vis Sci 54:1247","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6271_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF00131022","volume":"11","author":"R Brancato","year":"1988","unstructured":"Brancato R, Menchini U, Pece A, Capoferri C, Avanza P, Radrizzani E (1988) Dye laser photocoagulation of macular subretinal neovascularization in pathological myopia. A randomized study of three different wavelengths. Int Ophthalmol 11:235\u2013238","journal-title":"Int Ophthalmol"},{"key":"6271_CR31","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1097\/IAE.0000000000002292","volume":"39","author":"Y Chen","year":"2019","unstructured":"Chen Y, Sharma T, Li X, Song Y, Chang Q, Lin R, Egger A, Foo A, Gekkieva M, Lai TYY (2019) Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: brilliance, a 12-month, randomized, double-masked study. Retina 39:1985\u20131994. https:\/\/doi.org\/10.1097\/IAE.0000000000002292","journal-title":"Retina"},{"key":"6271_CR32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000478030","volume":"238","author":"C Calvo-Gonz\u00e1lez","year":"2017","unstructured":"Calvo-Gonz\u00e1lez C, Reche-Frutos J, Fern\u00e1ndez-Vigo JI, S\u00e1enz-Franc\u00e9s F, Fern\u00e1ndez-P\u00e9rez C, Garc\u00eda-Feij\u00f3o J (2017) Long-term outcomes of two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal neovascularization. Ophtalmologica 238:196\u2013204","journal-title":"Ophtalmologica"},{"key":"6271_CR33","doi-asserted-by":"publisher","unstructured":"Cha DM, Kim TW, Heo JW, Woo SJ, Park KH, Yu HG, Chung H (2014) Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study. BMC Ophthalmol 14:69. https:\/\/doi.org\/10.1186\/1471-2415-14-69","DOI":"10.1186\/1471-2415-14-69"},{"key":"6271_CR34","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1136\/bjo.2006.103606","volume":"91","author":"WM Chan","year":"2007","unstructured":"Chan WM, Lai TY, Wong AL, Liu DT, Lam DS (2007) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 91:174\u2013189. https:\/\/doi.org\/10.1136\/bjo.2006.103606","journal-title":"Br J Ophthalmol"},{"key":"6271_CR35","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1097\/IAE.0b013e3182109074","volume":"31","author":"L Chen","year":"2011","unstructured":"Chen L, Miller JW, Vavvas D, Kim IK (2011) Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration. Retina 31:2078\u20132083. https:\/\/doi.org\/10.1097\/IAE.0b013e3182109074","journal-title":"Retina"},{"key":"6271_CR36","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1080\/02713683.2020.1742357","volume":"45","author":"C Chen","year":"2020","unstructured":"Chen C, Yan M, Huang Z, Song Y-P (2020) The evaluation of a two-year outcome of intravitreal conbercept versus ranibizumab for pathological myopic choroidal neovascularization. Curr Eye Res 45:1415\u20131421. https:\/\/doi.org\/10.1080\/02713683.2020.1742357","journal-title":"Curr Eye Res"},{"key":"6271_CR37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/01.iae.0000244260.52901.2e","volume":"26","author":"RA Costa","year":"2006","unstructured":"Costa RA, Williams GA (2006) Two-fold illumination scheme for photodynamic therapy study group. Twofold illumination photodynamic therapy scheme for subfoveal choroidal neovascularization in pathologic myopia: results from a randomized pilot study. Retina 26:757\u2013764. https:\/\/doi.org\/10.1097\/01.iae.0000244260.52901.2e","journal-title":"Retina"},{"key":"6271_CR38","first-page":"2204","volume":"51","author":"G Dethorey","year":"2010","unstructured":"Dethorey G, Leveziel N, Glacet-Bernard A, Lalloum F, Hay A, Tahiri R, Champion E, Souied EH (2010) Efficacy of ranibizumab versus PDT in myopic choroidal neovascularisation. Invest Ophthalmol Vis Sci 51:2204","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6271_CR39","first-page":"38","volume":"236","author":"A El Habbak","year":"2016","unstructured":"El Habbak A, El Nagar M, Tawfik T, El Zaher MA, El Shiwy H, Howaidy A, Falougy A (2016) Comparison of intravitreal aflibercept injection versus intravitreal ranibizumab injection in patients with myopic choroidal neovascularization. Ophthalmologica J Int d\u2019ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkunde 236:38\u201339","journal-title":"Ophthalmologica J Int d'ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkunde"},{"key":"6271_CR40","doi-asserted-by":"publisher","unstructured":"Erden B, B\u00f6l\u00fckba\u015f\u0131 S, Ba\u015f E, \u00c7ak\u0131r A (2019) Comparison of intravitreal aflibercept and ranibizumab for treatment of myopic choroidal neovascularization: one-year results-a retrospective, comparative study. J Ophthalmol 2019:8639243. https:\/\/doi.org\/10.1155\/2019\/8639243","DOI":"10.1155\/2019\/8639243"},{"key":"6271_CR41","doi-asserted-by":"publisher","first-page":"887","DOI":"10.5301\/ejo.5000323","volume":"23","author":"C Farinha","year":"2013","unstructured":"Farinha C, Baltar AS, Nunes SG, Franqueira NF, Figueira JP, Pires IA, Cachulo ML, Silva RM (2013) Choroidal thickness after treatment for myopic choroidal neovascularization. Eur J Ophthalmol 23:887\u2013898. https:\/\/doi.org\/10.5301\/ejo.5000323","journal-title":"Eur J Ophthalmol"},{"key":"6271_CR42","first-page":"4936","volume":"54","author":"RD Fern\u00e1ndez","year":"2013","unstructured":"Fern\u00e1ndez RD, Govetto A, Alves Perez MT, Lorente R (2013) Ranibizumab versus bevacizumab in the treatment of subfoveal choroidal neovascular membrane secondary to pathologic myopia. Invest Ophthalmol Vis Sci 54:4936","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"6271_CR43","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1097\/IAE.0b013e31827d260a","volume":"33","author":"E Wang","year":"2013","unstructured":"Wang E, Chen Y (2013) Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 33(7):1375\u201392. https:\/\/doi.org\/10.1097\/IAE.0b013e31827d260a","journal-title":"Retina"},{"key":"6271_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000360307","volume":"232","author":"P Freitas-da-Costa","year":"2014","unstructured":"Freitas-da-Costa P, Pinheiro-Costa J, Carvalho B, Falc\u00e3o M, Brand\u00e3o E, Falc\u00e3o-Reis F, Carneiro \u00c2 (2014) Anti-VEGF therapy in myopic choroidal neovascularization: long-term results. Ophtalmologica 232:57\u201363. https:\/\/doi.org\/10.1159\/000360307","journal-title":"Ophtalmologica"},{"key":"6271_CR45","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ajo.2009.10.010","volume":"149","author":"M Gharbiya","year":"2010","unstructured":"Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, Gabrieli CB (2010) Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab\u2013a randomized controlled trial. Am J Ophthalmol 149:458\u2013464. https:\/\/doi.org\/10.1016\/j.ajo.2009.10.010","journal-title":"Am J Ophthalmol"},{"key":"6271_CR46","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ajo.2007.10.032","volume":"145","author":"K Hayashi","year":"2008","unstructured":"Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hara W, Yoshida T, Tokoro T, Mochizuki M (2008) Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol 145:518\u2013526","journal-title":"Am J Ophthalmol"},{"key":"6271_CR47","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ajo.2009.03.026","volume":"148","author":"K Hayashi","year":"2009","unstructured":"Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W, Yoshida T, Tokoro T, Mochizuki M (2009) Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 148:396\u2013408. https:\/\/doi.org\/10.1016\/j.ajo.2009.03.026","journal-title":"Am J Ophthalmol"},{"key":"6271_CR48","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1097\/IAE.0b013e31826956b7","volume":"32","author":"P Iacono","year":"2012","unstructured":"Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, Bandello F (2012) Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 32:1539\u20131546. https:\/\/doi.org\/10.1097\/IAE.0b013e31826956b7","journal-title":"Retina"},{"key":"6271_CR49","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1097\/IAE.0000000000001436","volume":"37","author":"P Iacono","year":"2017","unstructured":"Iacono P, Battaglia Parodi M, Selvi F, Parravano MC, Chiaravalloti A, Varano M, Bandello F (2017) Factors influencing visual acuity in patients receiving anti-vascular endothelial growth factor for myopic choroidal neovascularization. Retina 37:1931\u20131941. https:\/\/doi.org\/10.1097\/IAE.0000000000001436","journal-title":"Retina"},{"key":"6271_CR50","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ajo.2009.08.008","volume":"149","author":"Y Ikuno","year":"2010","unstructured":"Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T, Takahashi K, Uchihori Y, Gomi F (2010) Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 149:140\u2013146. https:\/\/doi.org\/10.1016\/j.ajo.2009.08.008","journal-title":"Am J Ophthalmol"},{"key":"6271_CR51","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/eye.2012.75","volume":"26","author":"U Introini","year":"2012","unstructured":"Introini U, Casalino G, Querques G, Gimeno AT, Scotti F, Bandello F (2012) Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization. Eye 26:976\u2013982","journal-title":"Eye"},{"key":"6271_CR52","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1097\/IAE.0000000000001421","volume":"37","author":"EC Kang","year":"2017","unstructured":"Kang EC, Seo JG, Kim BR, Koh HJ (2017) Clinical outcomes of intravitreal bevacizumab versus photodynamic therapy with or without bevacizumab for myopic choroidal neovascularization: a 7-year follow-up study. Retina 37:1775\u20131783. https:\/\/doi.org\/10.1097\/IAE.0000000000001421","journal-title":"Retina"},{"key":"6271_CR53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1089\/jop.2019.0080","volume":"36","author":"A Korol","year":"2020","unstructured":"Korol A, Kustryn T, Zadorozhnyy O, Pasyechnikova N, Kozak I (2020) Comparison of efficacy of intravitreal ranibizumab and aflibercept in eyes with myopic choroidal neovascularization: 24-month follow-up. J Ocul Pharmacol Ther 36:122\u2013125","journal-title":"J Ocul Pharmacol Ther"},{"key":"6271_CR54","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/eye.2012.97","volume":"26","author":"TY Lai","year":"2012","unstructured":"Lai TY, Luk FO, Lee GK, Lam DS (2012) Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye 26:1004\u20131011. https:\/\/doi.org\/10.1038\/eye.2012.97","journal-title":"Eye"},{"key":"6271_CR55","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/ceo.13424","volume":"47","author":"S Li","year":"2019","unstructured":"Li S, Ding X, Sun L, Zhao X, Zhang A, Lyu C, Liu B, Zhang J, Jin C, Lu L (2019) Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study. Clin Exp Ophthalmol 47:250\u2013258. https:\/\/doi.org\/10.1111\/ceo.13424","journal-title":"Clin Exp Ophthalmol"},{"key":"6271_CR56","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5301\/EJO.2011.7750","volume":"22","author":"M Matsuo","year":"2012","unstructured":"Matsuo M, Honda S, Matsumiya W, Kusuhara S, Tsukahara Y, Negi A (2012) Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization. Eur J Ophthalmol 22:210\u2013215","journal-title":"Eur J Ophthalmol"},{"key":"6271_CR57","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik J-F, Vitti R, Li T, Stemper B, Asmus F, Zeitz O, Ishibashi T (2015) Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 122:1220\u20131227","journal-title":"Ophthalmology"},{"key":"6271_CR58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000330499","volume":"47","author":"Y Niwa","year":"2012","unstructured":"Niwa Y, Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M (2012) Comparison between one injection and three monthly injections of intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Res 47:135\u2013140. https:\/\/doi.org\/10.1159\/000330499","journal-title":"Ophthalmic Res"},{"key":"6271_CR59","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1167\/iovs.09-4191","volume":"51","author":"B Pal","year":"2010","unstructured":"Pal B, Degli Esposti S, DeZaeytijd J, Rahman W, Adatia F, Hamilton RD, Tufail A (2010) Visual outcome in myopic choroidal neovascularisation following anti-VEGF (bevacizumab or ranibizumab) therapy compared to photodynamic treatment (PDT) or observation. Invest Ophthalmol Vis Sci 51:2197","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"6271_CR60","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1097\/IAE.0000000000000201","volume":"34","author":"M Parravano","year":"2014","unstructured":"Parravano M, Ricci F, Oddone F, Missiroli F, De Felici C, Varano M (2014) Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization. Retina 34(10):2053\u201362. https:\/\/doi.org\/10.1097\/IAE.0000000000000201","journal-title":"Retina"},{"key":"6271_CR61","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s00417-014-2886-x","volume":"253","author":"A Pece","year":"2015","unstructured":"Pece A, Milani P, Monteleone C (2015) A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV. Graefes Arch Clin Exp Ophthalmol 253:1867\u20131872","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6271_CR62","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, Wong TY, Silva R, Pilz S, Gekkieva M, RADIANCE Study Group (2014) RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121:682\u2013692. https:\/\/doi.org\/10.1016\/j.ophtha.2013.10.023","journal-title":"Ophthalmology"},{"key":"6271_CR63","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00417-016-3498-4","volume":"255","author":"M Rinaldi","year":"2017","unstructured":"Rinaldi M, Semeraro F, Chiosi F, Russo A, Romano MR, Savastano MC, dell\u2019Omo R, Costagliola C (2017) Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 255:529\u2013539","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6271_CR64","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4103\/0301-4738.81049","volume":"59","author":"P Rishi","year":"2011","unstructured":"Rishi P, Rishi E, Venkataraman A, Gopal L, Sharma T, Bhende M, Ratra D, Sen PR, Sen P (2011) Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia. Indian J Ophthalmol 59:242\u2013246","journal-title":"Indian J Ophthalmol"},{"key":"6271_CR65","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1136\/bjophthalmol-2015-307802","volume":"100","author":"P Rishi","year":"2016","unstructured":"Rishi P, Rishi E, Bhende M, Agarwal V, Vyas CH, Valiveti M, Bhende P, Rao C, Susvar P, Sen P, Raman R, Khetan V, Murali V, Ratra D, Sharma T (2016) Comparison of photodynamic therapy, ranibizumab\/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre. Br J Ophthalmol 100:1337\u20131340","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"6271_CR66","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.ophtha.2011.07.029","volume":"118","author":"JM Ruiz-Moreno","year":"2011","unstructured":"Ruiz-Moreno JM, L\u00f3pez-G\u00e1lvez MI, Donate J, Gomez-Ulla F, Garc\u00eda-Arum\u00ed J, Garc\u00eda-Layana A, Sell\u00e9s I, Reche J, Montero JA, Pazos B, Zapata MA, Pastor JC (2011) Myopic choroidal neovascularization. Ophthalmology 118(12):2521\u20133. https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.029","journal-title":"Ophthalmology"},{"key":"6271_CR67","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00417-010-1599-z","volume":"249","author":"JM Ruiz-Moreno","year":"2011","unstructured":"Ruiz-Moreno JM, Montero JA, Amat-Peral P (2011) Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefes Arch Clin Exp Ophthalmol 249:595\u2013599. https:\/\/doi.org\/10.1007\/s00417-010-1599-z","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6271_CR68","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1111\/j.1755-3768.2010.02070.x","volume":"90","author":"JM Ruiz-Moreno","year":"2012","unstructured":"Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva RDPP (2012) Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization. Acta Ophthalmol 90:e82-83. https:\/\/doi.org\/10.1111\/j.1755-3768.2010.02070.x","journal-title":"Acta Ophthalmol"},{"key":"6271_CR69","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1136\/bjophthalmol-2012-302973","volume":"97","author":"JM Ruiz-Moreno","year":"2013","unstructured":"Ruiz-Moreno JM, Arias L, Montero JA, Carneiro \u00c2, Silva R (2013) Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Br J Ophthalmol 97:1447\u20131450","journal-title":"Br J Ophthalmol"},{"key":"6271_CR70","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.ophtha.2013.03.006","volume":"120","author":"JM Ruiz-Moreno","year":"2013","unstructured":"Ruiz-Moreno JM, L\u00f3pez-G\u00e1lvez MI, Montero JA, Pastor JC (2013) Intravitreal bevacizumab in myopic neovascular membranes: 24-month results. Ophtalmology 120:1510\u20131511. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.006","journal-title":"Ophtalmology"},{"key":"6271_CR71","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1097\/IAE.0000000000000632","volume":"35","author":"JM Ruiz-Moreno","year":"2015","unstructured":"Ruiz-Moreno JM, Montero JA, Araiz J, Arias L, Garc\u00eda-Layana J, Carneiro \u00c2, Figueroa MS, Silva R (2015) Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia: six years outcome. Retina 35:2450\u20132456. https:\/\/doi.org\/10.1097\/IAE.0000000000000632","journal-title":"Retina"},{"key":"6271_CR72","first-page":"335","volume":"7","author":"S Saviano","year":"2014","unstructured":"Saviano S, Piermarocchi R, Leon EP, Mangogna A, Zanei A, Cavarzeran F, Tognetto D (2014) Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: a one-year follow-up controlled study. Int Ophthalmol 7:335\u2013339","journal-title":"Int Ophthalmol"},{"key":"6271_CR73","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00417-018-04214-w","volume":"257","author":"K Sayanagi","year":"2019","unstructured":"Sayanagi K, Uematsu S, Hara C, Wakabayashi T, Fukushima Y, Sato S, Ikuno Y, Nishida K (2019) Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 257:749","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6271_CR74","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1097\/IAE.0000000000000610","volume":"35","author":"D Siu-Chun","year":"2015","unstructured":"Siu-Chun D, Kwok AKH, Tong JMK, Chan CWN, Li WWT (2015) Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization. Retina (Philadelphia, Pa) 35:2457\u20132468. https:\/\/doi.org\/10.1097\/IAE.0000000000000610","journal-title":"Retina (Philadelphia, Pa)"},{"key":"6271_CR75","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/s0161-6420(02)01998-x","volume":"110","author":"KJ Blinder","year":"2003","unstructured":"Verteporfin in Photodynamic Therapy (VIP) Study Group, Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial\u2013VIP report no.3. Ophthalmology 110:667\u2013673. https:\/\/doi.org\/10.1016\/s0161-6420(02)01998-x","journal-title":"Ophthalmology"},{"key":"6271_CR76","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/s0161-6420(01)00544-9","volume":"108","author":"Verteporfin in Photodynamic Therapy (VIP) Study Group","year":"2001","unstructured":"Verteporfin in Photodynamic Therapy (VIP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial-VIP report no 1. Ophthalmology 108:841\u2013852. https:\/\/doi.org\/10.1016\/s0161-6420(01)00544-9","journal-title":"Ophthalmology"},{"key":"6271_CR77","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00417-009-1285-1","volume":"248","author":"B Voykov","year":"2010","unstructured":"Voykov B, Gelisken F, Inhoffen W, Voelker M, Bartz-Schmidt KU, Ziemssen F (2010) Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol 248:543\u2013550. https:\/\/doi.org\/10.1007\/s00417-009-1285-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6271_CR78","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/IAE.0b013e3181f2a293","volume":"31","author":"T Wakabayashi","year":"2011","unstructured":"Wakabayashi T, Ikuno Y, Gomi F (2011) Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Retina (Philadelphia, Pa) 31:880\u2013886. https:\/\/doi.org\/10.1097\/IAE.0b013e3181f2a293","journal-title":"Retina (Philadelphia, Pa)"},{"key":"6271_CR79","doi-asserted-by":"publisher","first-page":"14389","DOI":"10.1038\/s41598-018-32761-z","volume":"8","author":"JK Wang","year":"2018","unstructured":"Wang JK, Huang TL, Chang PY, Chen YT, Chang CW, Chen FT, Hsu YR, Chen YJ (2018) Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization. Sci Rep 8:14389. https:\/\/doi.org\/10.1038\/s41598-018-32761-z","journal-title":"Sci Rep"},{"key":"6271_CR80","first-page":"4745","volume":"59","author":"M Woronkowicz","year":"2018","unstructured":"Woronkowicz M, Lightman S, Hamilton R, Zagora S, Tomkins-Netzer O (2018) Comparison of anatomical and functional outcomes of treatment with bevacizumab and ranibizumab injections in eyes with myopic choroidal neovascularization (mCNV). Invest Ophthalmol Vis Sci 59:4745","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6271_CR81","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/IAE.0b013e3181bd2fe4","volume":"30","author":"JU Yoon","year":"2010","unstructured":"Yoon JU, Byun YJ, Koh HJ (2010) Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 30:418\u2013424. https:\/\/doi.org\/10.1097\/IAE.0b013e3181bd2fe4","journal-title":"Retina"},{"key":"6271_CR82","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/IAE.0b013e318227a9ef","volume":"32","author":"JU Yoon","year":"2012","unstructured":"Yoon JU, Kim YM, Lee SJ, Byun YJ, Koh HJ (2012) Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization. Retina 32:949\u2013955. https:\/\/doi.org\/10.1097\/IAE.0b013e318227a9ef","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06271-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06271-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06271-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T23:33:32Z","timestamp":1716248012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06271-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["6271"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06271-2","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"29 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}